------------------ | ------------------ | --------------- | ||||||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging Growth Company |
(amounts in millions) | Three months ended June 30, 2021 | Three months ended June 30, 2021 vs. 2020 | Six months ended June 30, 2021 | Six months ended June 30, 2021 vs. 2020 | |||||||||||||||||||
Total Revenue | $ | 1,700 | 18 | % | $ | 3,337 | 15 | % | |||||||||||||||
SOLIRIS Revenue | $ | 1,071 | 10 | % | $ | 2,099 | 5 | % | |||||||||||||||
ULTOMIRIS Revenue | $ | 354 | 41 | % | $ | 701 | 48 | % | |||||||||||||||
C5 Franchise Revenue | $ | 1,425 | 16 | % | $ | 2,800 | 13 | % | |||||||||||||||
STRENSIQ Revenue | $ | 208 | 13 | % | $ | 405 | 14 | % | |||||||||||||||
KANUMA Revenue | $ | 33 | (3) | % | $ | 67 | 12 | % | |||||||||||||||
ANDEXXA Revenue | $ | 35 | ** | $ | 64 | ** |
Date: July 20, 2021 | ALEXION PHARMACEUTICALS, INC. | ||||
By: /s/ Doug Barry | |||||
Name: Doug Barry | |||||
Title: Vice President, Corporate Law | |||||
Cover Page Statement |
Jul. 20, 2021 |
---|---|
Cover [Abstract] | |
Title of 12(g) Security | Common Stock, par value $0.0001 per share |
Entity Emerging Growth Company | false |
Written Communications | false |
Entity Incorporation, State or Country Code | DE |
Entity Central Index Key | 0000899866 |
Document Type | 8-K |
Document Period End Date | Jul. 20, 2021 |
Entity Registrant Name | ALEXION PHARMACEUTICALS, INC. |
Entity Address, Address Line One | 121 Seaport Boulevard |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02210 |
City Area Code | 475 |
Local Phone Number | 230-2596 |
Amendment Flag | false |
Entity File Number | 000-27756 |
Entity Tax Identification Number | 13-3648318 |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Trading Symbol | ALXN |
Security Exchange Name | NASDAQ |
GT3/9XA
M+@^H$WI"*\!K(_#,U+7HCTDFILAN8O0]C.=0XIS_4R/5-9:PIK)SX&7HD<$F
M@SXTV :MO'%0Z!6=@=76'$'M))I)ZRE>?&]3#5$3?5,
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